Express Scripts adds VOQUEZNA to national formularies for commercial plans

Phathom Pharmaceuticals, Inc.

Express Scripts, a leading U.S. PBM, added VOQUEZNA to its national formularies for commercial plans, effective immediately.
Formulary placement offers access to VOQUEZNA with a single step through a generic proton pump inhibitor (PPI).
Expanded formulary access may drive uptake of Phathom's approved product VOQUEZNA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.